[의약품]Intellectual Wellness, LLC 대 GenX Labs 간의 의약품 관련 특허 분쟁
발생일자 2015.03.13
사건번호 2:15-cv-10955
법원국가 UNITED STATES OF AMERICA
관할법원명 D.C.E.D.Michigan(지방법원)
침해권리 특허
원고명 Intellectual Wellness, LLC ( 미국 / NPEs )
피고명 GenX Labs ( 미국 / 외국기업 )
소송유형 침해금지
분쟁내용
[Intellectual Wellness, LLC v. GenX Labs] 사건번호 2:15-cv-10955에 따르면 원고 Intellectual Wellness, LLC는 피고 GenX Labs을 상대로 특허 US8338399|US8778918을 침해하였다는 이유로 미국 미시건 동부 지방법원에 소를 제기하였다. 원고 Intellectual Wellness, LLC는 또한 동일 특허 침해를 이유로 Powerlab Nutrition, LLC를 상대로도 같은 날 동일법원에 소를 제기하였다.
분쟁결과 분쟁중
산업분류 화학∙바이오 > 의약품
계쟁제품 "19 Nor Andro (Super 1- DHEA)" - Dietary supplement products
지재권번호/명칭
US8338399 Use of DHEA derivatives for enhancing physical performance
US8778918 Use of 19 nor DHEA derivatives for enhancing physical performance
Use of DHEA derivatives for enhancing physical performance
Abstract
A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.
Claims
What is claimed is:
1. A method of administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof as a compound that provides at least one of anti-aging adrenal hormonal balance, decreased body weight, reduction of adipose tissue, increased endurance, skeletal muscle growth, and increased production of red blood cells, of the general formula: ##STR00007## wherein R3 is one of .alpha.-OH and .beta.-OH, R5 is one of .alpha.-H and .beta.-H, and R7 is one of .alpha.-H and .beta.-H.
2. The method of claim 1 wherein the DHEA derivative is administered in one of the following ways: orally, transdermally, intranasally, by injection, sublingually, and transrectally.
3. The method of claim 1 wherein the DHEA derivative is administered in the form of a gel capsule.
4. The method of claim 1 further comprising administering the DHEA derivative with creatine.
5. A method of administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof as a compound that provides at least one of anti-aging adrenal hormonal balance, decreased body weight, reduction of adipose tissue, increased endurance, skeletal muscle growth, and increased production of red blood cells, of one of the following general formulae: ##STR00008## wherein R3 is one of .alpha.-OH and .beta.-OH, R5 is one of .alpha.-H and .beta.-H, and R7 is one of .alpha.-H and .beta.-H.
6. The method of claim 5 wherein the DHEA derivative is administered in one of the following ways: orally, transdermally, intranasally, by injection, sublingually, and transrectally.
7. The method of claim 5 wherein the DHEA derivative is administered in the form of a gel capsule.
8. The method of claim 5 further comprising administering the DHEA derivative with creatine.
9. The method of claim 5 wherein the DHEA derivative is administered as a daily dosage between about 50 mg and 2000 mg.
10. The method of claim 5 wherein the DHEA derivative is administered as a daily dosage between about 100 mg and 400 mg.
11. The method of claim 5 wherein the DHEA derivative is administered as a daily dosage between about 50 mg to 200 mg twice per day.
12. The method of claim 5 wherein the DHEA derivative is administered as a daily dosage between about 25 mg to 100 mg four times per day.
Use of 19 nor DHEA derivatives for enhancing physical performance
Abstract
A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.
Claims
What is claimed is:
1. A method of administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof as a compound that provides at least one of anti-aging adrenal hormonal balance, decreased body weight, reduction of adipose tissue, increased endurance, skeletal muscle growth, and increased production of red blood cells, of the general formula: ##STR00007## wherein R3 is one of .alpha.-OH and .beta.-OH.
2. The method of claim 1 wherein the DHEA derivative is administered in one of the following ways: orally, transdermally, intranasally, by injection, sublingually, and transrectally.
3. The method of claim 1 wherein the DHEA derivative is administered as a daily dosage between about 50 mg and 2000 mg.
4. The method of claim 1 wherein the DHEA derivative is administered as a daily dosage between about 100 mg and 400 mg.
5. The method of claim 1 wherein the DHEA derivative is administered as a daily dosage between about 50 mg to 200 mg twice per day.
6. The method of claim 1 wherein the DHEA derivative is administered as a daily dosage between about 25 mg to 100 mg four times per day.
7. The method of claim 1 wherein the DHEA derivative is administered in the form of a gel capsule.
8. The method of claim 1 further comprising administering the DHEA derivative with creatine.
![[US Patent & Trademark Office, Patent Full Text and Image Database]](http://patft.uspto.gov/netaicon/PTO/patfthdr.gif)
